News | Heart Failure | May 31, 2022

VECTOR-HF I Study Confirms Safety and Accuracy of V-LAP In-Heart Sensor for Left Atrial Pressure Management of Heart Failure

First clinical data of implantable heart sensor with remote measurement capabilities presented at prestigious Late-Breaking Science forum at the ESC Heart Failure 2022

First clinical data of implantable heart sensor with remote measurement capabilities presented at prestigious Late-Breaking Science forum at the ESC Heart Failure 2022

May 31, 2022 — Vectorious Medical Technologies Ltd., an innovator in implantable hemodynamic monitoring in heart failure (HF),  announced results of VECTOR-HF I, a first-in-man clinical study demonstrating the robust safety, ease of use, and accuracy of its pioneering V-LAP novel wireless system. The V-LAP system is implanted permanently in the left atrial wall of the heart to remotely calculate left atrial pressure (LAP).

The VECTOR-HF I data was presented on May 22 during a prestigious late-breaking science forum at the European Society of Cardiology (ESC) Heart Failure 2022 and is the first clinical data from this study to be made public. Late-breaking sessions highlight the most innovative and promising advances in heart failure research and offer special recognition for studies likely to have a significant impact on clinical care of patients.

The V-LAP system is the first device to directly measure pressure data generated from the left atrium, the most specific and comprehensive indication for fluid accumulation and the culmination of a decade of work by Vectorious Medical Technologies. By enabling physicians to have direct access to LA pressure readings remotely, heart failure treatment has the potential to be more personalized, accurate and timely, beginning even before physiological symptoms appear.

In this prospective, multisite, open label, single-arm study, V-LAP intracardiac sensors were implanted in 30 patients with moderate to severe HF. The study showed that implantation and positioning of the sensor in the intra-atrial wall are simple-to-master and safe procedures. Further, it confirmed that the sensor transmitted accurate LAP measurements, as measured at 3 months post procedure and compared to pulmonary capillary wedge pressure (PCWP) data.

The VECTOR-HF I study also provided early indications of clinical benefit of direct LAP measurement, based on improvement in well-established quality-of-life metrics.

Eyal Orion, Co-founder and CEO, Vectorious Medical Technologies: “The promising results of the VECTOR-HF I study are a major step in confirming our long-held belief that the V-LAP system is safe, durable, and accurate. Remote, real-time access to LAP changes is key to providing optimal treatment to heart failure patients and keeping these patients out of the hospital, living longer, better lives. Implanting a sensor in the heart is a challenging mission we took on ourselves a decade ago. Our results show that the V-LAP technology provides valuable long-term information from the patient’s heart, not just data. This will enable us to create a scalable platform to treat millions of heart failure patients and efficiently address a variety of comorbidities inside and outside the heart.”

Professor Filippo Crea, Director of the Department of Cardiovascular and Pneumological Sciences of the University Hospital Agostino Gemelli in Rome and a principal investigator for the VECTOR-HF studies: “The increase of left atrial pressure is a specific and early sign of impending heart failure exacerbation – long before clinical symptoms occur. Its non-invasive monitoring might substantially improve the management of patients with chronic heart failure. Although the VECTOR-HF I trial was not powered to evaluate efficacy or impact on patient outcomes, preliminary data demonstrated how early diuretics change, based on increased LA pressure, helps to stabilize patients.”

Given the success of VECTOR-HF I in meeting its endpoints, a second prospective, multi-center study, VECTOR-HF II, started enrolling patients in Europe in January 2022, with goals of achieving a cohort of 20 patients. This ongoing study aims to assess a patient app that is designed as part of the V-LAP system to enable heart failure patients to take an active role in managing their disease for the first time.

Lessons learned from VECTOR-HF II will be incorporated into VECTOR-HF III, a larger pivotal study which is scheduled to begin in the US in 2023 with the goal of achieving FDA approval.

For more information: https://vectoriousmedtech.com/

Related Content

News | ESC

June 1, 2022 — Eating low glycaemic index foods promotes a healthier body shape in patients with coronary artery disease ...

Home June 01, 2022
Home
News | ESC

May 9, 2022 — Heart failure presents differently in women and men – discover the latest evidence and its impact on ...

Home May 09, 2022
Home
News | ESC

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

Home March 31, 2022
Home
News | ESC

January 3, 2022 — The following is a list of the 2021 news stories from the European Society of Cardiology (ESC) ...

Home January 03, 2022
Home
News | ESC | By Dave Fornell, DAIC Editor

October 4, 2021 — Here are links to all the late-breaking cardiology studies presented in Hot-Line sessions at the 2021 ...

Home October 04, 2021
Home
News | ESC

The European Society of Cardiology (ESC) will host several Hot Lines sessions that will include some of the latest ...

Home July 21, 2020
Home
News | ESC

May 6, 2020 — The European Society of Cardiology (ESC), one of the world's largest cardiovascular conferences, is ...

Home May 06, 2020
Home
Feature | ESC

September 9, 2019 — More than 33,000 health professionals gathered over five days to attend the 2019 European Society of ...

Home September 09, 2019
Home
News | ESC

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively ...

Home September 12, 2017
Home
News | ESC

September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by ...

Home September 12, 2017
Home
Subscribe Now